Biotech

All Articles

Actinogen's cortisol blocker stops working stage 2 depression research

.Actinogen Medical's cortisol blocker has actually missed the key endpoint of a stage 2 study in cli...

Bivictrix decides going exclusive only means to take ADC right into clinic

.Antibody-drug conjugates (ADCs) have gone to the facility of many a billion-dollar biobuck licensin...

TPG leadings up funds to $580M for financial investments all over lifestyle scientific researches

.Resource manager TPG, which has assisted biotechs like Sionna Rehabs and also Santa Clam Ana Biogra...

Merck ceases phase 3 TIGIT trial in lung cancer cells for futility

.Merck &amp Co.'s TIGIT program has actually suffered one more obstacle. Months after shuttering a p...

After a challenging year, Exscientia folds up in to Recursion

.After a year specified through pipeline hairstyles, the variation of its own chief executive office...

Cullinan, after $25M package, hands back bispecific to Harbour

.Cullinan Therapeutics was excited sufficient along with Harbour BioMed's bispecific immune system a...

A nearer examine Brutal Biotech's Strong 15

.In this particular full week's episode of "The Top Line," we're diving in to Brutal Biotech's yearl...

Lilly faces phase 2 breakdown of tau-targeting med

.The confetti is still soaring from Eli Lilly's party celebrating the commendation of Alzheimer's he...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our roundup of considerable management hirings, firings and ...

Lykos will certainly ask FDA to rethink its choice observing denial of MDMA therapy for trauma

.Observing an unsatisfactory presenting for Lykos Rehabs' MDMA prospect for trauma at a recent FDA a...